New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

An expanded collaboration between the two organizations will focus on prostate cancer and metastatic liver tumors, in addition to neurodegenerative disease.